Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, indicating progress in its research and development efforts [1] Group 1: Clinical Trials - The approved clinical trials include JIZM01 for closed soft tissue contusions and joint sprains [1] - The second trial is for JIZM02, which targets shoulder periarthritis [1]

JIZM02功能主治为：祛风除湿、活血通络、行气止痛。用于肩关节周围炎风湿痹痛证，症见肩部疼 痛，肿胀，屈伸不利。肩关节周围炎的治疗原则是针对病症的不同时期或症状严重程度采取相应的治疗 措施，包括药物治疗、物理治疗、针灸、针刀及手术治疗等。常用的治疗药物为非甾体抗炎药及中成药 制剂，如消尔痛酊、蟾马正痛酊、骨痛灵酊等。JIZM02组方精炼，无毒性药材，可为该类患者提供一 种安全有效的治疗方式。 JIZM01和JIZM02获得临床试验资格对公司的财务状况、经营业绩不构成重大影响。根据我国药品注册 相关的法律法规要求，药物在获得药物临床试验批准通知书后，尚需开展临床试验并经国家药监局审 评、审批通过后方可生产上市。 格隆汇9月24日丨九典制药(300705.SZ)公布，近日收到国家药品监督管理局签发的《药物临床试验批准 通知书》，在完成相关准备工作后将开展临床试验研究。JIZM01功能主治为：活血通络，消肿止痛。 用于闭合性软组织损伤引起的疼痛、肿胀、瘀斑、功能障碍。在临床应用中，软组织损伤主要治疗方式 以局部给药为主，常用药物有云南白药、红花油、活络油、消痛贴膏、少林风湿跌打膏等。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, indicating progress in its research and development efforts [1] Group 1 - The company has obtained a clinical trial approval notice for JIZM01, which is intended for the treatment of closed soft tissue contusions and joint sprains [1] - The clinical trial for JIZM02 has been approved, targeting adhesive capsulitis of the shoulder [1]

Core Viewpoint - Jizhen Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of drugs JIZM01 and JIZM02, indicating progress in its research and development efforts [1] Group 1: Company Developments - Jizhen Pharmaceutical announced on September 24 that it has obtained the clinical trial approval for drugs JIZM01 and JIZM02 [1] - JIZM01 is intended for the treatment of closed soft tissue contusions and joint sprains [1] - JIZM02 is aimed at treating periarthritis of the shoulder [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, JIZM01 and JIZM02, targeting specific medical conditions [1] Group 1: Drug Information - JIZM01 is intended for the treatment of closed soft tissue contusions and joint sprains [1] - JIZM02 is designed for shoulder periarthritis [1] Group 2: Regulatory Approval - The approval was granted in accordance with the Drug Administration Law of the People's Republic of China and relevant regulations [1] - The company will commence clinical trial research after completing the necessary preparatory work [1]